FDA safety alert for compounded glutamine, arginine, and carnitine product for injection by United Pharmacy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

ISSUE: FDA received an adverse event report stating that two patients developed what is described in the report as tissue erosion at the injection site following the administration of an injectable glutamine, arginine, and carnitine (GAC) product that was compounded by United Pharmacy, LLC, located in West Palm Beach, Florida. According to the report, a sample of the product was sent for testing and the pH was determined to be above 11. FDA conducted a for-cause inspection of United Pharmacy and collected samples from two batches of GAC injectable product. Analysis performed on the samples determined the pH to be 10.9, which is alkaline, and no glutamine was detected. Parenteral drugs, including compounded injectable drugs, with a high pH may lead to skin damage or other unintended health consequences.

Compounded drugs have not been evaluated by FDA for safety, effectiveness, and quality. There is no FDA-approved injectable GAC product.

BACKGROUND: United Pharmacy recalled lots GAC-12 and GAC-13 on September 27, 2017.

RECOMMENDATION: Compounding pharmacies should be aware of saf...

Recommended for you

  • MedWatch Drug Updates
  • 1 comment

FDA Safety Alert - Becton-Dickinson replaced problematic rubber stoppers in its syringes

  • MedWatch Drug Updates
  • 1 comment

Anaphylaxis and other serious hypersensitivity reactions reported with use of Varubi (rolapitant) injectable emulsion

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Reprocessed Agilis Steerable Introducer Sheath by Sterilmed: Improper seal of sheath hub

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Certitude Delivery System by Edwards Lifesciences due to a mold overflow defect

  • MedWatch Drug Updates
  • 1 comment

Recall of Clopidogrel Tablets, USP 75 mg by International Laboratories due to mislabeling

  • MedWatch Drug Updates
  • no comment

Recall of Ampicillin and Sulbactam for Injection USP, 1.5 g/vial by Auromedics: Presence of glass particles

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Defibrillation Electrodes by Physio-Control: Artwork shows incorrect placement instruction for infants

  • MedWatch Drug Updates
  • 1 comment

Recall of Compounded Sterile Products by PharMEDium Services due to lack of sterility assurance

  • MedWatch Drug Updates
  • 1 comment

Recall of Linezolid Injection 600mg/300mL flexible bags by AuroMedics Pharma: Presence of particulate matter

  • MedWatch Drug Updates
  • 1 comment

Recall of Riomet (Metformin Hydrochloride Oral Solution) by Sun Pharmaceutical: Presence of microbial contamination

  • MedWatch Drug Updates
  • 1 comment

Recall of Pantoprazole Sodium Injection 40 mg per vial by AuroMedics Pharma: Presence of glass particles

  • MedWatch Drug Updates
  • 1 comment

Long-acting beta agonists and inhaled corticosteroids: FDA removed boxed warning about asthma-related death from labels

  • MedWatch Drug Updates
  • 1 comment

FDA warning: Gadolinium retention in patients body after receiving gadolinium-based contrast agents (GBCAs)

  • MedWatch Drug Updates
  • 1 comment

FDA update: Type III endoleaks associated with the use of endovascular graft systems

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Bridge Occlusion Balloon Catheter Model 590-001 by Spectranetics: Blocked guidewire lumen

  • MedWatch Drug Updates
  • 1 comment

FDA update: High risk of mortality and neurological adverse events when using SynCardia's TAH-t C2 Driver System

  • MedWatch Drug Updates
  • 1 comment

Recall of pharmacist choice alcohol prep pads by simple diagnostics due to quality concerns.

  • FDA Drug Updates
  • 1 comment

FDA approved Mvasi (bevacizumab-awwb) for the treatment of cancer

  • FDA Drug Updates
  • 1 comment

FDA approved Aliqopa (copanlisib) for the treatment of relapsed follicular lymphoma

  • MedWatch Drug Updates
  • 1 comment

Fading print on label of AlbuRx 25, Albumin (Human) 25% solution

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Intra-Aortic Balloon Pump by Datascope/MAQUET- False blood detection alarm and ingress of fluid into the pump

  • MedWatch Drug Updates
  • 1 comment

FDA recommends separate dosing for Kayexalate (sodium polystyrene sulfonate) from all other oral drugs

  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Biotin (Vitamin B7) interferes with certain lab tests

  • MedWatch Drug Updates
  • 1 comment

FDA statement on risks of unapproved use of Keytruda (pembrolizumab) for treatment of multiple myeloma

  • MedWatch Drug Updates
  • 1 comment

Recall of Piyanping Anti-Itch Lotion by Lucky Mart Inc.: Contain wrong active pharmaceutical ingredient

  • FDA Drug Updates
  • 1 comment

FDA approves Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia

  • MedWatch Drug Updates
  • 1 comment

FDA investigated life-threatening adverse events associated with Limbrel Capsules by Primus Pharmaceuticals

  • MedWatch Drug Updates
  • 1 comment

Recall of Diphenoxylate Hydrochloride and Atropine Sulfate by Greenstone: Sub-potent or super-potent product

  • FDA Drug Updates
  • 1 comment

New targeted treatment approved for relapsed or refractory acute myeloid leukemia

  • MedWatch Drug Updates
  • no comment

FDA safety alert: Increased risk of heart-related death with febuxostat (Uloric)